Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor
Status:
Completed
Trial end date:
2019-09-02
Target enrollment:
Participant gender:
Summary
The aim of this study in subjects with obstructive sleep apnea is to investigate
pharmacodynamics, safety and tolerability after a single nasal administration of BAY2253651
and to evaluate first safety and tolerability of multiple dosing over 5 consecutive nights in
OSA patients.